Table 6 Baseline characteristics of 120 PMN patients for detecting circulating anti-PLA2R antibody
PLA2R low risk + HLA low risk | PLA2R low risk + HLA high risk | PLA2R high risk + HLA low risk | PLA2R high risk + HLA high risk | P | |
|---|---|---|---|---|---|
n = 12 | n = 7 | n = 60 | n = 41 | ||
Male/female | 8/4 | 4/3 | 36/24 | 24/17 | 0.963 |
Age (year) | 48.33 ± 15.47 | 54.86 ± 15.08 | 49.95 ± 15.28 | 52.71 ± 9.30 | 0.564 |
Scr (μmol/L) | 79.75 ± 28.70 | 73.78 ± 22.95 | 72.87 ± 39.41 | 73.30 ± 27.08 | 0.935 |
Urea (mmol/L) | 5.78 ± 1.90 | 6.08 ± 2.74 | 6.43 ± 5.19 | 5.48 ± 2.21 | 0.707 |
eGFR (ml/ (min·1.73m2)) | 94.49 ± 27.64 | 91.90 ± 27.57 | 99.98 ± 23.42 | 94.26 ± 21.48 | 0.577 |
Urine protein (g/24 h) | 8.30 ± 7.67 | 3.30 ± 2.07 | 4.73 ± 3.68 | 4.38 ± 3.09 | 0.010 |
HGB (g/L) | 132.25 ± 17.11 | 132.14 ± 15.66 | 132.08 ± 15.72 | 133.07 ± 17.52 | 0.993 |
Alb (g/L) | 23.11 ± 5.67 | 28.44 ± 7.23 | 25.74 ± 5.89 | 32.40 ± 38.65 | 0.465 |
anti-PLA2R ( +)/ ( −) | 5/7 | 5/2 | 45/15 | 36/5 | 0.012 |
anti-PLA2R ( +) (%) | 41.6 | 71.4 | 75.0 | 87.8 |